Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma

Bone Marrow Transplant. 2021 Mar;56(3):683-685. doi: 10.1038/s41409-020-01029-4. Epub 2020 Aug 11.

Authors

Talha Badar¹, Bryon D Johnson¹, Mehdi Hamadani²

Affiliations

¹ BMT and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
² BMT and Cellular Therapy Program, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. mhamadani@mcw.edu.

PMID: 32782349
DOI: 10.1038/s41409-020-01029-4

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD19* / therapeutic use
Biological Products
Humans
Immunotherapy, Adoptive
Lymphoma, Large B-Cell, Diffuse* / drug therapy

Substances

Antigens, CD19
Biological Products
axicabtagene ciloleucel